NCT02864992 2025-12-23Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)EMD SeronoPhase 2 Active not recruiting337 enrolled 13 charts 2 FDA
NCT03329690 2022-03-18DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]Daiichi SankyoPhase 2 Completed233 enrolled 26 charts 1 FDA